FCGR2A and myasthenia gravis: Table 1 summarizes each therapeutic and includes dosing and pharmacodynamic (PD) information from the phase 1 clinical trials that were critical to inform the subsequent clinical trials in MG patients. Pharmacokinetic (PK) parameters for each therapeutic may be found in the phase 1 and phase 2 manuscripts cited below. Other FcRn targeted strategies, such as recombinant Fc multimers and FcγR targeted therapeutics, and additional FcRn monoclonal antibodies are in development but have not yet entered clinical testing for MG (20, 21).